Bionano Genomics, Inc. (BNGO) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Financial performance shows a revenue decline but improved margins and cost reductions. Product development highlights growth in flowcell utilization and software adoption. However, market competition and system returns pose risks. The Q&A reveals opportunities for software expansion and strategic partnerships but also highlights uncertainties in system returns and reimbursement pricing. Overall, the sentiment is neutral, reflecting balanced positive and negative factors without a clear catalyst for significant stock price movement.
Key Financial Performance
Total Revenue $6.7 million, a decrease of 13% year-over-year. The decrease was primarily due to $700,000 in revenues from discontinued services in 2024, which did not contribute to 2025 revenues. Adjusting for these discontinued services, the revenue decrease was 5% year-over-year.
Flowcells Sold 7,233 flowcells, reflecting a 17% increase year-over-year. This growth is attributed to efforts towards driving utilization within the routine-use customer group.
Non-GAAP Gross Margin 52%, significantly higher than the 35% reported a year ago. The improvement is due to cost reduction and improvements in product manufacturing costs.
Non-GAAP Operating Expenses $8.8 million, a 53% reduction year-over-year from $18.8 million. This reduction reflects cost-cutting measures and a reduction in headcount by more than 300 people since Q2 2023.
Installed Optical Genome Mapping Systems 378 systems installed, a net decrease of 1 system in the quarter but a 4% increase year-over-year from 363 systems as of June 30, 2024.
Recurring Routine-Use Revenue (Consumables and Software Sales) 16% year-over-year growth in Q2 2025. As a percentage of the total product mix, consumables and software revenue increased from 55% in Q2 2024 to 73% in Q2 2025. This growth is driven by increased utilization and a reduction in new instrument sales.
Cash, Cash Equivalents, and Available-for-Sale Securities $27.4 million at the end of the quarter, of which $11 million was subject to certain restrictions.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VIA 7.2, Solve 3.8.3, and Stratys Compute updates: Released updates to software suite and compute solutions, including VIA 7.2, Solve 3.8.3, and Stratys Compute platform. These updates enhance AI-driven workflows for hematologic malignancies and constitutional genetic disorders, improve structural variant detection, and double cancer sample analysis capacity.
Pathology market focus: Shifted focus to digital pathology, particularly cytogenetics and molecular pathology, with potential expansion into clinical and anatomic pathology.
Revenue and cost management: Q2 2025 revenue was $6.7 million, a 5% year-over-year decrease when adjusted for discontinued services. Non-GAAP gross margin improved to 52% from 35% a year ago. Non-GAAP operating expenses reduced by 53% year-over-year, with over $100 million in annual cost reductions since 2023.
Flowcell sales growth: Sold 7,233 flowcells in Q2 2025, a 17% year-over-year increase, with 14% growth among existing customers.
Recurring revenue growth: Consumables and software sales grew 16% year-over-year in Q2 2025, increasing their share of total product mix from 55% to 73%.
Strategic shift in focus: Implemented a strategy to prioritize routine users of OGM and VIA products, aiming to drive revenue and profit growth through higher utilization and menu expansion.
Reimbursement and guidelines support: Achieved a second Category I CPT code for OGM in constitutional genetic disorders, supporting reimbursement and adoption.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Total revenue for Q2 2025 decreased by 13% compared to Q2 2024, with a 5% decrease even after adjusting for discontinued services. This decline could impact financial stability and growth.
Net Decrease in Installed Systems: The company experienced a net decrease of 1 in the installed base of optical genome mapping systems, which could hinder growth in customer acquisition and utilization.
Cash Constraints: The company ended the quarter with $27.4 million in cash, of which $11 million is subject to restrictions, potentially limiting operational flexibility.
Dependence on Routine Users: The strategy focuses heavily on a subset of routine users for revenue growth, which could be risky if these users reduce or stop their usage.
Regulatory and Reimbursement Challenges: While progress has been made, the company still faces hurdles in achieving widespread reimbursement and inclusion in medical guidelines for its optical genome mapping technology.
Market Competition: The pathology market is evolving with advancements in sequencing technologies, which could pose competitive threats to the company's optical genome mapping solutions.
Operational Cost Reductions: The company has significantly reduced operating expenses and headcount, which, while improving margins, could strain resources and impact operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company reiterates its full-year revenue guidance of $26 million to $30 million. For Q3 2025, revenues are expected to be in the range of $6.7 million to $7.2 million.
OGM System Installations: The company has raised its expectations for new Optical Genome Mapping (OGM) system installations in 2025 to be in the range of 20 to 25, up from the prior range of 15 to 20.
Gross Margin Outlook: Non-GAAP gross margin for Q2 2025 was 52%, and the company expects continued margin expansion over time but anticipates remaining around the current levels in the near term.
Software and Consumables Growth: Recurring revenue from consumables and software sales grew 16% year-over-year in Q2 2025 and 8% year-over-year for the first half of 2025. This growth is expected to continue as part of the company's strategy to focus on routine-use customers.
Product Updates and Releases: The company plans a broad commercial release of its updated software suite, including VIA 7.2, Solve 3.8.3, and Stratys Compute platform, later in 2025. These updates are expected to enhance the adoption and utilization of OGM.
Reimbursement and Market Adoption: The establishment of a second Category I CPT code for OGM by the American Medical Association is expected to pave the way for increased routine use of OGM in cytogenetics and constitutional genetic disorders.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How universal is the use of VIA software among OGM users?
A:VIA is installed in about 1/3 of the OGM systems overall, but adoption is much higher among routine-use customers. There is significant opportunity to expand its adoption and utilization, especially with new updates for constitutional genetic disorders.
Q:Are there efforts to market VIA to non-OGM users?
A:Yes, VIA is marketed to non-OGM users for applications like long-read sequencing, structural variation detection, and analysis. These customers represent an opportunity for cross-selling OGM units, though direct adoption is not guaranteed.
Q:What role does AI play in the VIA software?
A:AI helps analyze databases to identify and categorize variants, accelerating and improving the results of the analysis.
Q:Why were 8 systems brought back during the quarter?
A:The 8 systems were returned by users who were not routine users. These were part of a reagent rental program, and the returns were primarily from research-oriented applications, influenced by funding constraints.
Q:What is the return or attrition rate among new systems placed?
A:It is too early to provide a return rate for the new systems placed under the current strategy. The expectation is that these systems will not be returned, though it is acknowledged that some returns may occur.
Q:How is the second Category I CPT code different from the first, and how will it facilitate reimbursement?
A:The second code is for constitutional genetic disorders, while the first is for hematologic malignancies. The workflows and supporting literature differ, and the new code could potentially have different pricing. Draft pricing is expected in September.
Q:Why does the instrument placing guidance assume a slight decline in the back half of the year?
A:The guidance reflects conservatism, as installations from a potential budget flush in Q4 could spill over into the first quarter of 2026.
Q:What drove the growth in flowcell utilization, and how long does it take new customers to ramp up utilization?
A:Growth was driven by focused customer support, training programs, and installations from late last year. It typically takes 6-9 months for new customers to reach routine use and repurchase consumables.
Q:How is Bionano thinking about strategic partnerships or dealmaking?
A:Bionano is open to strategic partnerships and is on the radar of potential acquirers. The company is focused on its digital pathology transformation strategy but acknowledges its advanced position in the market for potential deals.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the return or attrition rate among new systems placed, stating it was too early to determine. Additionally, they did not provide specific details on the pricing of the second Category I CPT code, as it is still pending.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
BTIG LLC
Bais BTIG
CEO CFO
CFO Director
Chen HC
Co LLC
Director Okunewitch
Division Unidentified
Division Vidyun
Division Yi
Dr Holmlin
ET day
Group LLC
HC Wainwright
Holmlin CEO
LLC Research
Okunewitch Maxim
President CEO
Reconciliation measure
Relations Unidentified
Relations measure
Research Division
Unidentified Conference
Unidentified Investor
Vidyun Bais
Wainwright Co
Yi Chen
circumstance Investor
deck recording
information investor
investor Reconciliation
measure information
BNGO Transcript
Bionano Genomics, Inc. (BNGO) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call reveals a mixed financial performance: a 15% revenue increase and improved gross margin are positive, but rising operating expenses and net loss are concerning. The lack of strategic updates and forward-looking caution adds uncertainty. Overall, the sentiment is neutral, reflecting balanced positives and negatives.
Bionano Genomics, Inc. (BNGO) Q4 2025 Earnings Call Transcript
Unknown3-23
The earnings call presented mixed signals: a decline in software revenue and geographic narrowing suggest challenges, while improved margins and cost reductions are positive. The Q&A revealed management's reluctance to provide specific guidance, raising uncertainties. However, the expected revenue growth and potential catalysts like the CPT code price increase offer some optimism. Overall, the sentiment is neutral due to balanced positive and negative factors, and without market cap data, a more precise prediction is challenging.
Bionano Genomics, Inc. (BNGO) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings report indicates positive financial performance with revenue growth and improved margins, but there are concerns regarding liquidity constraints and profitability challenges. The Q&A session highlighted uncertainties in achieving target utilization levels and market expansion timelines. Despite a new CPT code and increased system installations, the dependency on routine users and economic uncertainties pose risks. The recent stock offering and restricted cash further temper optimism. Given these mixed signals, the stock price is expected to remain relatively stable over the next two weeks.
Bionano Genomics, Inc. (BNGO) Q2 2025 Earnings Call Transcript
Unknown8-15
The earnings call presents a mixed picture. Financial performance shows a revenue decline but improved margins and cost reductions. Product development highlights growth in flowcell utilization and software adoption. However, market competition and system returns pose risks. The Q&A reveals opportunities for software expansion and strategic partnerships but also highlights uncertainties in system returns and reimbursement pricing. Overall, the sentiment is neutral, reflecting balanced positive and negative factors without a clear catalyst for significant stock price movement.
BNGO Slides
BNGO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
